REGN Regeneron Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: REGN

Price (delayed)

$618.03

Market cap

$64.79B

P/E Ratio

14.52

Dividend/share

$3.64

EPS

$42.56

Enterprise value

$64.54B

?
Relative Growth: Rel. Growth: 55
Relative Strength: Rel. Strength: 32
Relative Valuation: Rel. Valuation: 63
Relative Profitability: Rel. Profitability: 83

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it ...

Highlights
REGN's price to earnings (P/E) is 14% lower than its 5-year quarterly average of 16.7 and 7% lower than its last 4 quarters average of 15.4
The equity has grown by 7% year-on-year
The quick ratio has contracted by 27% YoY and by 13% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.regeneron.com/
Peers: AMGN ALNY BIIB NVS

Key stats

What are the main financial stats of REGN

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
0.9%
1 week
0.54%
1 month
-3.26%
1 year
20.73%
YTD
-19.93%
QTD
-20.01%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$14.92B
Gross profit
$12.61B
Operating income
$3.63B
Net income
$4.42B
Gross margin
84.5%
Net margin
29.6%
Regeneron Pharmaceuticals's operating margin has decreased by 11% YoY and by 2.4% QoQ
The net margin has decreased by 7% YoY and by 6% from the previous quarter
The revenue has increased by 6% YoY and by 4% QoQ
The operating income fell by 5% YoY

Price vs fundamentals

How does REGN's price correlate with its fundamentals

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
REGN P/E details
P/E
14.52
P/B
2.08
P/S
4.31
EV/EBIT
12.4
EV/EBITDA
11.23
EV/Sales
4.33
REGN's price to earnings (P/E) is 14% lower than its 5-year quarterly average of 16.7 and 7% lower than its last 4 quarters average of 15.4
REGN's price to book (P/B) is 38% less than its 5-year quarterly average of 3.3 and 10% less than its last 4 quarters average of 2.3
The equity has grown by 7% year-on-year
The P/S is 26% lower than the 5-year quarterly average of 5.8 and 9% lower than the last 4 quarters average of 4.7
The revenue has increased by 6% YoY and by 4% QoQ

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
The return on assets has declined by 8% year-on-year and by 3.5% since the previous quarter
Regeneron Pharmaceuticals's return on equity has decreased by 8% YoY and by 3.4% QoQ
The company's return on sales fell by 5% QoQ and by 2.2% YoY
Regeneron Pharmaceuticals's return on invested capital has decreased by 2.6% QoQ

Dividends

What is REGN's dividend history
Dividend details
DPS
$3.64
Dividend yield
0.59%
Payout ratio
8.6%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Regeneron Pharmaceuticals financials performed over time
The current ratio is down by 28% YoY and by 14% QoQ
The quick ratio has contracted by 27% YoY and by 13% from the previous quarter
The debt is 91% less than the equity
The equity has grown by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.